N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine

• ChemBase ID: 1262
• Molecular Formular: C15H21N
• Molecular Mass: 215.33394
• Monoisotopic Mass: 215.16739968
• SMILES: N(C1C2CC(C1c1ccccc1)CC2)CC
• Canonical SMILES: CCNC1C2CCC(C1c1ccccc1)C2
• InChI: InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
• InChIKey: IKFBPFGUINLYQI-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
• IUPAC Traditional name: fencamfamine
• Brand Name: Glucoenergan; Reactivan; Euvitol
• Synonyms: Fencamfamin; Fencamfamin hydrochloride; Fencamfamine [inn-french]; Fencamfamine hydrochloride; Fencamfaminum [inn-latin]; Fencanfamina [inn-spanish]; Fencamfamina [dcit]; 2-Ethylamino-3-phenylnorcamphane hydrochloride; 2-Ethylamino-3-phenyl-norcamphane hydrochloride; 2-Aethylamino-3-phenyl-nor-camphan; Fencamfamine

Database IDs

• CAS Number: 1209-98-9
• PubChem SID: 46508161; 160964722
• PubChem CID: 14584

CALCULATED PROPERTIES

JChem

• H Acceptors: 1
• H Donor: 1
• LogD (pH = 5.5): -0.029843722
• LogD (pH = 7.4): 0.3056124
• Log P: 3.2056742
• Molar Refractivity: 67.6398 cm^3
• Polarizability: 26.954664 Å^3
• Polar Surface Area: 12.03 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 3.46
• LOG S: -4.86
• Solubility (Water): 2.95e-03 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 3.20 [SANGSTER (1994)]

DETAILS

DrugBank - DB01463

• Drug Groups: illicit; approved; withdrawn
• Description: Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases. [Wikipedia]
• Indication: For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.
• Pharmacology: Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.
• Toxicity: Overdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.
• Affected Organisms: Humans and other mammals
• References: [Link] ; DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3. [Pubmed]
• External Links: Wikipedia

REFERENCES

• Link
• DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3. Pubmed